Most Popular Stories
- DNA sequencing exposes new uses for Pfizer targeted cancer drugs
- Preclinical study triggers 'massive response' from desperate Alzheimer's patients
- Hungry Valeant snags Eyetech in ongoing buyout spree
- Chelsea shares nosedive on FDA's questions about key drug
- Ben Venue can't say when crucial cancer drug will be available
- GSK studies Chinese remedies to discover new drugs
- GSK studies Chinese remedies to discover new drugs
- Chelsea shares nosedive on FDA's questions about key drug
- DNA sequencing exposes new uses for Pfizer targeted cancer drugs
- Preclinical study triggers 'massive response' from desperate Alzheimer's patients
- Hungry Valeant snags Eyetech in ongoing buyout spree
Webinars
- Biomarkers and Translational Medicine in Early Phase Oncology Clinical Development (Part two of our three part series) Increasingly, new technologies are making it possible to carefully identify sets of patien
- Inside the mHealth Revolution with Welch Allyn: Realizing the Potential of Connected DevicesAfter launching a line of connected devices, Welch Allyn immediately viewed it as an oppor
- Prepare Your Compliance Systems and Processes for the Physician Payments Sunshine ActBeginning in 2012, pharmaceutical, biotechnology and medical device companies will be requ
- Getting the most out of First-in-Human and Early Clinical TrialsIn a follow-up to our webinar last month on first-in-human drug studies, FierceBiotech edi
Featured Jobs
-
Associate Manager, Global Supply Chain Planning (1 of 3) Job
Celgene Corporation - Basking Ridge, NJ, US -
Docket Clerk Job
Celgene Corporation - Summit, NJ, US -
District Sales Manager – Hematology, Denver / Phoenix Job
Celgene Corporation - Denver, CO, US -
Product Manager, Channel Marketing Job
Celgene Corporation - Summit, NJ, US -
Clinical Research Associate
Jennerex, Inc - San Francisco, CA
Events
- Pharmaceutical Strategic Outlook
April 11-13, 2012 - World Orphan Drug Congress USA 2012
10-13 April, 2012 — Gaylord National Resort and Convention Center, Washington, D.C. - Connect, Collaborate, & Innovate: MassBio Annual Meeting
March 26-27 — Cambridge, MA - DCAT Week '12 Biologics Forum & Networking Reception
Mar 14 — New York City
Free Newsletter
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
Popular Topics
Whitepapers
- Displacement Chromatography Comes of Age - An indispencable tool for the purification of biomacromolecules
- Central Nervous System (CNS) Compound Library from OTAVA
- Avoiding Post-Acquisition Product Sales Failures
- API in Capsule: Common "First in Man" approaches vs. The Lost Art of Formulation Development
- Let travelers smell your rich media content
- Pharma 2.0: Heading Toward Social Media Marketing
Biography for Liz Jones Hollis
Liz Hollis is the editor-at-large in the Life Sciences group at FierceMarkets. Before joining the company, she was the editor of Generic Line at FDAnews, where she also held the position of eZine editor. She also has worked at the Competitive Enterprise Institute as assistant editorial director. She loves the Chicago Bears, running and dogs. She is based at the FierceMarkets main office in Washington, D.C., and can be reached at ehollis@fiercemarkets.com. Follow @FiercePharma on Twitter and find her on LinkedIn.
Articles by Liz Jones Hollis
- March 17, 2011
- February 28, 2011
- February 28, 2011
- February 28, 2011
- February 28, 2011
- February 28, 2011
- February 15, 2011
- February 15, 2011
- February 14, 2011
- February 13, 2011
- February 4, 2011
- February 4, 2011
- January 28, 2011
- January 21, 2011
- January 20, 2011
- January 20, 2011
- January 20, 2011
- January 20, 2011
- January 19, 2011
- January 14, 2011
- January 13, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
